Document is current
Any future updates will be listed below
-
Authors
Aldeeva, Iuliia A. https://orcid.org/0009-0005-3133-3283
Glebova, Elena V. https://orcid.org/0000-0003-3553-1234
Sarkisyan, Roza A. https://orcid.org/0000-0002-9142-5375
Romanova, Elizaveta N. https://orcid.org/0000-0002-8568-0118
Karpova, Nadezhda M. https://orcid.org/0000-0002-4546-6926
Shapovalova, Valeriia G. https://orcid.org/0009-0005-0966-6452
Karelin, Alexander F. https://orcid.org/0000-0001-6383-2822
-
Funding
Funding for this research was provided by:
RUDN University (212202-2-000)
- License Information
-
More Information
Article History
Received: 3 April 2025
Accepted: 2 May 2025
First Online: 16 May 2025
Declarations
:
: This study was approved by the Ethics Committee of Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology (protocol number 8/2017 of 24.10.2017). Information about the trial was provided to participants and their parents/legal representatives. Written informed consent was obtained from all participants or their parents/legal representatives.
: This study suggests that pediatric medulloblastoma patients treated with the HIT protocol experience cognitive decline that worsens after the completion of active treatment. Longer duration of remission is associated with poorer scores on cognitive tests which underscores the importance of continuous monitoring and targeted rehabilitative interventions for medulloblastoma survivors.
: The authors declare no competing interests.
